FDA approves IV Poteligeo for Treating Two Rare types of Cutaneous T cell lymphoma (CTCL)
Shots:
- FDA approves Kyowa Kirin’s Poteligeo drug for R/R Mycosis fungoides (MF) and Sézary syndrome (SS)
- Poteligeo received Orphan Drug designation with addition permission granted on basis of Priority Review and Breakthrough Therapy
- The approval is based on a clinical trial of 372 patients with MF or SS. Study reported mPFS (Poteligeo vs Vorinostat) is 7.6mos vs 3.1mos
/ | Ref: US FDA | Image: BioNJ
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com